Ramoplanin CAS NO.:76168-82-6
Active Pharmaceutical Ingredients 2025-03-11
CAS NO.:76168-82-6
Molecular formula:C106H170ClN21O30
Molecular weight:2254.079
Standard:enterprise standard
Content：≥95.0%
Packaging:100g/BAG
Use to：glycopeptides
Ramoplanin: A Promising Antibacterial Agent
Ramoplanin is a lipoglycodepsipeptide antibiotic with unique properties, which makes it valuable in treating certain bacterial infections.
1. General and Pharmacokinetic Information
| Aspect | Details |
| Source | Produced by Actinoplanes ATCC 33076 |
| Chemical Class | Lipoglycodepsipeptide |
| Administration | Oral administration (as it has poor systemic absorption, mainly used for local effects in the gastrointestinal tract) |
| Distribution | Mainly remains in the gastrointestinal lumen; limited systemic distribution due to poor absorption |
| Metabolism | Not well – characterized, but likely undergoes minimal metabolism in the body |
| Elimination | Excreted mainly in feces, as it is not absorbed systemically to a significant extent |
2. Mechanism of Action
| Action | Explanation |
| Inhibition of Cell Wall Synthesis | Ramoplanin binds to the lipid – II molecule in the cell wall of Gram – positive bacteria. Lipid – II is a key intermediate in peptidoglycan synthesis. By binding to lipid – II, ramoplanin blocks the transglycosylation step, which is crucial for the elongation of peptidoglycan chains. This disruption in cell wall synthesis leads to cell death. Additionally, it may also interfere with the proper localization of cell wall – synthesizing enzymes. |
3. Clinical Applications and Adverse Effects
| Category | Details |
| Clinical Applications | Primarily used for the treatment of Clostridioides difficile – associated diarrhea (CDAD). It targets C. difficile in the gastrointestinal tract, helping to reduce the symptoms and recurrence of CDAD. Since it acts locally in the gut, it has the advantage of minimizing systemic side effects while effectively treating the infection at the site of action. |
| Adverse Effects | Generally well – tolerated. Some patients may experience mild gastrointestinal side effects such as nausea, vomiting, and diarrhea, which can be expected considering its action in the gut. However, these side effects are usually less severe compared to some other antibiotics used for CDAD treatment. There is also a low risk of developing resistance, which is an important advantage in the context of treating a difficult – to – treat pathogen like C. difficile. |
Ramoplanin offers a useful option for treating specific gastrointestinal infections, especially those related to C. difficile, with a relatively favorable safety and efficacy profile.
